1. Home
  2. CLH vs GMAB Comparison

CLH vs GMAB Comparison

Compare CLH & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Clean Harbors Inc.

CLH

Clean Harbors Inc.

HOLD

Current Price

$305.16

Market Cap

16.0B

Sector

Industrials

ML Signal

HOLD

Logo Genmab A/S ADS

GMAB

Genmab A/S ADS

HOLD

Current Price

$27.13

Market Cap

16.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CLH
GMAB
Founded
1980
1999
Country
United States
Denmark
Employees
N/A
3029
Industry
Environmental Services
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
16.0B
16.9B
IPO Year
1994
N/A

Fundamental Metrics

Financial Performance
Metric
CLH
GMAB
Price
$305.16
$27.13
Analyst Decision
Buy
Strong Buy
Analyst Count
11
8
Target Price
$309.45
$39.81
AVG Volume (30 Days)
446.3K
1.6M
Earning Date
05-06-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
7.28
N/A
Revenue
$2,944,978,000.00
N/A
Revenue This Year
$4.58
$17.85
Revenue Next Year
$4.30
$16.04
P/E Ratio
$41.76
$1.90
Revenue Growth
N/A
N/A
52 Week Low
$201.34
$18.89
52 Week High
$316.98
$35.43

Technical Indicators

Market Signals
Indicator
CLH
GMAB
Relative Strength Index (RSI) 62.59 43.42
Support Level $276.65 $24.95
Resistance Level $316.98 $29.64
Average True Range (ATR) 7.04 0.58
MACD 0.12 0.06
Stochastic Oscillator 57.43 17.01

Price Performance

Historical Comparison
CLH
GMAB

About CLH Clean Harbors Inc.

Clean Harbors Inc is an environmental and industrial services provider that provides parts cleaning and related environmental services to commercial, industrial, and automotive customers. Its business segments are Environmental Services and Safety-Kleen Sustainability Solutions. Environmental Services includes waste collection, transportation, treatment, recycling, and disposal, along with industrial maintenance services. Safety-Kleen Sustainability Solutions provides used oil collection and manufactures base oil, vacuum gas oil, and lubricants. The company generates the majority of its revenues from the Environmental Services segment and operates in the United States, with maximum revenue, and Canada.

About GMAB Genmab A/S ADS

Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.

Share on Social Networks: